<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338191</url>
  </required_header>
  <id_info>
    <org_study_id>GIHSYSU-19</org_study_id>
    <nct_id>NCT04338191</nct_id>
  </id_info>
  <brief_title>mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer</brief_title>
  <acronym>FANTASTIC</acronym>
  <official_title>mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer Patients After Preoperative Treatment With Oxaliplatin (FANTASTIC): a Multicenter, Phase 3 Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard treatment for locally advanced rectal cancer is still fluorouracil-based&#xD;
      neoadjuvant radiotherapy and chemotherapy followed by TME surgery, followed by adjuvant&#xD;
      chemotherapy. Fluorouracil single-agent simultaneous sensitization of radiotherapy and&#xD;
      chemotherapy has a pCR of about 15-20% and a tumor downgrade (ypStage 0-I) rate of about 35%.&#xD;
      However, about 30% of patients still have distant metastasis, which is the main obstacle&#xD;
      affecting the survival prognosis of patients with locally advanced rectal cancer.&#xD;
&#xD;
      About 50% -65% of patients was still stage II-III after neoadjuvant therapy. The long-term&#xD;
      follow-up shows that for patients with ypT4 after surgery, the 3-year DFS is about 50%. For&#xD;
      patients with ypN2, the 3-year DFS is less than 40%. Therefore, it is necessary to strengthen&#xD;
      postoperative adjuvant chemotherapy to improve the survival prognosis for these patients.&#xD;
&#xD;
      Although FOLFOX adjuvant chemotherapy improved survival benefit than 5FU as adjuvant&#xD;
      treatment in ypStage II-III patients after neoadjuvant treatment in ADORE trial. However,&#xD;
      with the progress of neoadjuvant therapy research, more and more studies have proposed to&#xD;
      move part or all of postoperative adjuvant chemotherapy to preoperative neoadjuvant therapy&#xD;
      due to low compliance of adjuvant chemotherapy.&#xD;
&#xD;
      During neoadjuvant treatment, induction chemotherapy with FOLFOX / CAPEOX or consolidation&#xD;
      therapy after CRT with FOLFOX / CAPEOX had been investigated a lot. The pCR rate was 19%&#xD;
      -38%, and the tumor downstaging rate was about 50%. Another 50% of patients still had ypstage&#xD;
      II-III postoperatively. The 3-year DFS for ypStage III was only 55% even with FOLFOX as&#xD;
      adjuvant chemotherapy. And for ypT4N0 patients with ypstage IIB-IIC, there is also a higher&#xD;
      risk of recurrence and metastasis. And it is urgent to explore new treatment strategies to&#xD;
      improve this part of patients Survival prognosis.&#xD;
&#xD;
      For locally advanced colon cancer, surgery combined with postoperative adjuvant chemotherapy&#xD;
      is currently the standard treatment mode for stage II-III colon cancer. About 30% of patients&#xD;
      with locally advanced disease will relapse within 3 years, of which distant metastases are&#xD;
      more common and eventually become the main cause of death of patients. For locally advanced&#xD;
      colon cancer with a preoperative staging of T4b, the NCCN guidelines recommend surgery after&#xD;
      neoadjuvant chemotherapy with FOLFOX or CAPOX regimens. In the FOxTROT study of neoadjuvant&#xD;
      treatment of locally advanced colon cancer, for patients with T3&gt; 5mm or T4, after 4 courses&#xD;
      of neoadjuvant chemotherapy with FOLFOX regimen, 20.5% of patients still have T4 after&#xD;
      surgery, and 15.2% of patients had N2 disease. For this part of patients, new postoperative&#xD;
      treatment options should also be explored to improve patient survival and prognosis.&#xD;
&#xD;
      In view of the high efficiency of the three-agent FOLFOXIRI regimen in advanced colorectal&#xD;
      cancer and the success in adjuvant chemotherapy after pancreatic cancer surgery, 5FU,&#xD;
      oxaliplatin combined with irinotecan may have a synergistic effect. At present, a phase III&#xD;
      randomized controlled study (IROCAS study) in Europe is underway. For high-risk phase III&#xD;
      patients, the mFOLFOXIRI regimen is compared with mFOLFOX6 regimen adjuvant chemotherapy.&#xD;
&#xD;
      Based on the above reasons, our center plans to further carry out &quot;multi-center, randomized,&#xD;
      controlled phase III clinical study of mFOLFOXIRI versus mFOLFOX6 adjuvant chemotherapy after&#xD;
      neoadjuvant oxaliplatin in locally advanced colorectal cancer.&quot; Improve the survival&#xD;
      prognosis of postoperative high-risk colorectal cancer patients after neoadjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a two-arm, multicenter, open labelled, prospective, randomized phase III&#xD;
      studies. Eligible patients with locally advnaced colorectal cancer receiving oxlipaltin-based&#xD;
      (less than 3 months) noeadjuvant treatment, the postoperative stage was high-risk stage II&#xD;
      (ypT4N0M0) or stage III (ypTanyN1-2M0). These high risk patients will be randomly assigned,&#xD;
      in a 1:1 ratio, to receive either mFOLFOXIRI or FOLFOX for 3 months as adjuvant chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year Disease-free survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Defined as the time from randomization to relapse or death, whichever occurred first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Defined as the time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The grade of toxicity will be assessed using the NCI common toxicity criteria, version 5.0.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-C30 Quality of Life questionnaire</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by SF-36</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">638</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>mFOLFOXIRI adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive mFOLFOXIRI once every two weeks for 6 cycles as adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOX6 adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive mFOLFOX6 once every two weeks for 6 cycles as adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOXIRI adjuvant chemotherapy</intervention_name>
    <description>mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles</description>
    <arm_group_label>mFOLFOXIRI adjuvant chemotherapy</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6 adjuvant chemotherapy</intervention_name>
    <description>mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles</description>
    <arm_group_label>mFOLFOX6 adjuvant chemotherapy</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
          -  ECOG PS 0-1&#xD;
&#xD;
          -  Exposure to Oxaliplatin in preoperative treatment (less than 3 months)&#xD;
&#xD;
          -  Induction or consolidation chemotherapy in rectal cancer or Concurrent FOLFOX with CRT&#xD;
             in rectal cancer&#xD;
&#xD;
          -  Neoadjuvant treatment with CAPOX or FOLFOX in colon cancer&#xD;
&#xD;
          -  Curative surgery (R0 resection)&#xD;
&#xD;
          -  ypStage IIB, IIC and ypStage III&#xD;
&#xD;
          -  No distant metastasis after surgery&#xD;
&#xD;
          -  â‰¤ 8 weeks prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct in primary site or histology from colon&#xD;
             cancer within 5 years prior to randomization.&#xD;
&#xD;
          -  Significant cardiovascular disease including unstable angina or myocardial infarction&#xD;
             within 6 months before initiating study treatment.&#xD;
&#xD;
          -  Heart failure grade III/IV (NYHA-classification).&#xD;
&#xD;
          -  Unresolved toxicity higher than CTCAE v.4.0 Grade 1 attributed to any prior&#xD;
             therapy/procedure.&#xD;
&#xD;
          -  Subjects with known allergy to the study drugs or to any of its excipients.&#xD;
&#xD;
          -  Current or recent (within 4 weeks prior to starting study treatment) treatment of&#xD;
             another investigational drug or participation in another investigational study.&#xD;
&#xD;
          -  Breast- feeding or pregnant women&#xD;
&#xD;
          -  Lack of effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhong Deng, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanhong Deng, Ph.D.</last_name>
    <phone>008613925106525</phone>
    <email>13925106525@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianwei Zhang, M.D.</last_name>
    <phone>008613480216906</phone>
    <email>zhangjw25@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gastrointestinal Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhong Deng, M.D.</last_name>
      <phone>008613925106525</phone>
      <email>13925106525@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanhong Deng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Adjuvant chemotherpay</keyword>
  <keyword>FOLFOXIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

